There are currently no JCV-specific therapies available for clinical use. This study evaluates viral large T antigen (LTA) as a potential target for drug development. LTA is a hexameric protein with a helicase activity that is powered by ATP binding and hydrolysis. The helicase and ATPase function is critical for viral replication and inhibition by small molecules would disrupt the viral life cycle. LTA is a valid target for discovery of anti-JCV drugs. The hits identified are reasonable starting points for medicinal chemistry to improve potency and selectivity. Screening of additional chemical libraries could also be considered to identify chemical structures that may be more potent with acceptable cytotoxicity